[1]
|
Uccelli, A., Moretta, L. and Pistoia, V. (2008) Mesenchymal Stem Cells in Health and Disease. Nature Reviews Immunology, 8, 726-736. https://doi.org/10.1038/nri2395
|
[2]
|
Chawla, L.S., Eggers, P.W., Star, R.A. and Kimmel, P.L. (2014) Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes. The New England Journal of Medicine, 371, 58-66.
https://doi.org/10.1056/NEJMra1214243
|
[3]
|
Ozkok, A. and Edelstein, C.L. (2014) Pathophysiology of Cisplatininduced Acute Kidney Injury. BioMed Research International, 2014, Article ID: 967826.
|
[4]
|
Zhang, J., Goering, P.L., Espandiari, P., et al. (2009) Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine. Toxicologic Pathology, 37, 629-643. https://doi.org/10.1177/0192623309339605
|
[5]
|
Cepeda, V., Fuertes, M.A., Castilla, J., Alonso, C., Quevedo, C. and Pérez, J.M. (2007) Biochemical Mechanisms of Cisplatin Cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry, 7, 3-18.
https://doi.org/10.2174/187152007779314044
|
[6]
|
Zhu, S., Pabla, N., Tang, C., He, L. and Dong, Z. (2015) DNA Damage Response in Cisplatin-Induced Nephrotoxicity. Archives of Toxicology, 89, 2197-2205. https://doi.org/10.1007/s00204-015-1633-3
|
[7]
|
Ali, B.H. and Al Moundhri, M.S. (2006) Agents Ameliorating or Augmenting the Nephrotoxicity of Cisplatin and Other Platinum Compounds: A Review of Some Recent Research. Food and Chemical Toxicology, 44, 1173-1183.
https://doi.org/10.1016/j.fct.2006.01.013
|
[8]
|
Večerić-Haler, Ž., Cerar, A. and Perse, M. (2017) (Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity. Stem Cells Interna-tional, 2017, Article ID: 7304643.
|
[9]
|
Heyman, S.N., Rosen, S. and Rosenberger, C. (2009) Animal Models of Renal Dysfunction: Acute Kidney Injury. Expert Opinion on Drug Discovery, 4, 629-641.
|
[10]
|
Dobyan, D.C., Levi, J., Jacobs, C., Kosek, J. and Weiner, M.W. (1980) Mechanism of Cis-Platinum Nephrotoxicity: II. Morphologic Observations. The Journal of Pharmacology and Experi-mental Therapeutics, 213, 551-556.
|
[11]
|
Dobyan, D.C. (1985) Long-Term Consequences of Cis-Platinuminduced Renal Injury: A Structural and Functional Study. Anatomical Record, 212, 239-245. https://doi.org/10.1002/ar.1092120304
|
[12]
|
Sendao, M.C., Francescato, H.D., Antunes, L.M., Costa, R.S. and Bianchi Mde, L. (2006) Comparative Study of Multiple Dosage of Quercetin against Cisplatin-Induced Nephrotoxicity and Oxidative Stress in Rat Kidneys. Pharmacological Reports, 58, 526-532.
|
[13]
|
Amate, J.Y., Ishida, A., Tsujino, K., et al. (1996) Immunohistochemical Study of Rat Renal Interstitial Fibrosis Induced by Repeated Injection of Cisplatin, with Special Reference to the Kinetics of Macrophages and Myofibroblasts. Toxicologic Pathology, 24, 199-206. https://doi.org/10.1177/019262339602400208
|
[14]
|
Yamate, J., Sato, K., Ide, M., et al. (2002) Participation of Different Macrophage Populations and Myofibroblastic Cells in Chronically Developed Renal Interstitial Fibrosis after Cisplatin-Induced Renal Injury in Rats. Veterinary Pathology, 39, 322- 333. https://doi.org/10.1354/vp.39-3-322
|
[15]
|
Yamate, J., Machida, Y., Ide, M., et al. (2005) Cisplatin-Induced Renal Interstitial Fibrosis in Neonatal Rats, Developing as Solitary Nephron Unit Lesions. Toxicologic Pathology, 33, 207-217.
https://doi.org/10.1080/01926230490523978
|
[16]
|
Palant, C.E., Amdur, R.L. and Chawla, L.S. (2016) The Acute Kidney Injury to Chronic Kidney Disease Transition: A Potential Opportunity to Improve Care in Acute Kidney Injury. Contributions to Nephrology, 187, 55-72.
|
[17]
|
Palant, C.E., Chawla, L.S., Faselis, C., et al. (2016) High Serum Creatinine Nonlinearity: A Renal Vital Sign? American Journal of Physiology Renal Physiology, 311, F305-F309. https://doi.org/10.1152/ajprenal.00025.2016
|
[18]
|
Sharp, C.N. and Siskind, L.J. (2017) Developing Bettermouse Models to Study Cisplatin-Induced Kidney Injury. American Journal of Physiology Renal Physiology, 313, F835-F841. https://doi.org/10.1152/ajprenal.00285.2017
|
[19]
|
Skrypnyk, N.I., Siskind, L.J., Faube, S. and de Caestecker, M.P. (2016) Bridging Translation for Acute Kidney Injury with Better Preclinical Modeling of Human Disease. American Journal of Physiology Renal Physiology, 310, F972-F984. https://doi.org/10.1152/ajprenal.00552.2015
|
[20]
|
Rosen, S. and Heyman, S.N. (2001) Difficulties in Understanding Human “Acute Tubular Necrosis”: Limited Data and Flawed Animal Models. Kidney International, 60, 1220-1224. https://doi.org/10.1046/j.1523-1755.2001.00930.x
|
[21]
|
Heyman, S.N., Rosenberger, C. and Rosen, S. (2011) Acute Kidney Injury: Lessons from Experimental Models. Contributions to Nephrology, 169, 286-296. https://doi.org/10.1159/000313957
|
[22]
|
Kociba, R.J. and Sleight, S.D. (1971) Acute Toxicologic and Pathologic Effects of cis-Diamminedichloroplatinum (NSC-119875) in the Male Rat. Cancer Chemotherapy Reports, 55, 1-8.
|
[23]
|
Fillastre, J.P. and Raguenez-Viotte, G. (1989) Cisplatin Nephrotoxicity. Toxicology Letters, 46, 163-175.
https://doi.org/10.1016/0378-4274(89)90125-2
|
[24]
|
Yao, X., Panichpisal, K., Kurtzman, N. and Nugent, K. (2007) Cisplatin Ne-phrotoxicity: A Review. The American Journal of the Medical Sciences, 334, 115-124. https://doi.org/10.1097/MAJ.0b013e31812dfe1e
|
[25]
|
Dasari, S. and Tchounwou, P.B. (2014) Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. European Journal of Pharmacology, 740, 364-378. https://doi.org/10.1016/j.ejphar.2014.07.025
|
[26]
|
dos Santos, N.A.G., Rodrigues, M.A.C., Martins, N.M. and dos Santos, A.C. (2012) Cisplatin-Induced Nephrotoxicity and Targets of Nephroprotection: An Update. Archives of Toxicology, 86, 1233-1250.
https://doi.org/10.1007/s00204-012-0821-7
|
[27]
|
Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B. (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins (Basel), 2, 2490-2518. https://doi.org/10.3390/toxins2112490
|
[28]
|
Sanchez-Gonzalez, P.D., Lopez-Hernandez, F.J., Lopez-Novoa, J.M. and Morales, A.I. (2011) An Integrative View of the Pathophysiological Events Leading to Cisplatin Nephrotoxicity. Critical Reviews in Toxicology, 41, 803-821.
https://doi.org/10.3109/10408444.2011.602662
|
[29]
|
Okada, A., Fukushima, K., Fujita, M., et al. (2017) Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-Chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats. Biological & Pharmaceutical Bulletin, 40, 1948- 1955. https://doi.org/10.1248/bpb.b17-00499
|
[30]
|
Siddik, Z.H., Newell, D.R., Boxall, F.E. and Harrap, K.R. (1987) The Comparative Pharmacokinetics of Carboplatin and Cisplatin in Mice and Rats. Biochemical Pharmacology, 36, 1925-1932.
https://doi.org/10.1016/0006-2952(87)90490-4
|
[31]
|
Teobaldi, G., Hofer, W.A., Bikondoa, O., Pang, C.L. Cabailh, G. and Thornton, G. (2007) Modelling STM Images of TiO2(1 1 0) from First-Principles: Defects, Water Adsorption and Dissociation Products. Chemical Physics Letters, 437, 73-78. https://doi.org/10.1016/j.cplett.2007.01.068
|